VRDN
Viridian Therapeutics, Inc.\DE
NASDAQ · Healthcare · Biotechnology · US
$28.16
+11.97%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 14.27x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 4.82x
- Price / sales
- 44.85x
- Price / cash flow
- -9.57x
Enterprise value
- Enterprise value
- $2.5B
- EV / sales
- 35.85x
- EV / EBITDA
- -6.94x
- EV / EBIT
- -6.29x
- Market cap
- $3.2B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026